Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Dyne Therapeutics appoints Erick Lucera as CFO [Seeking Alpha]
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer [Yahoo! Finance]
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer